{"id":394502,"date":"2020-12-07T10:03:42","date_gmt":"2020-12-07T15:03:42","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=394502"},"modified":"2020-12-07T10:03:42","modified_gmt":"2020-12-07T15:03:42","slug":"sutro-biopharma-presents-data-from-ongoing-phase-1-dose-escalation-study-for-stro-001-for-the-treatment-of-b-cell-non-hodgkin-lymphoma-at-the-62nd-american-society-of-hematology-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-presents-data-from-ongoing-phase-1-dose-escalation-study-for-stro-001-for-the-treatment-of-b-cell-non-hodgkin-lymphoma-at-the-62nd-american-society-of-hematology-annual-meeting\/","title":{"rendered":"Sutro Biopharma Presents Data from Ongoing Phase 1 Dose-Escalation Study for STRO-001 for the Treatment of B-cell Non-Hodgkin Lymphoma at the 62nd American Society of Hematology Annual Meeting"},"content":{"rendered":"
\n

– STRO-001 was generally well-tolerated in patients with late-line NHL with no ocular or neuropathy toxicity signals; MTD has not been reached –<\/h2>\n

– 1 CR & 2 PRs observed in heavily pretreated patients with DLBCL; 1 SD in marginal zone lymphoma; 2 SDs in follicular lymphoma<\/h2>\n

– Fred Hutchinson preclinical models with STRO-001 identifies CD74 as a potential target for the treatment of AML<\/h2>\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n SOUTH SAN FRANCISCO, Calif.<\/span>, Dec. 7, 2020<\/span> \/PRNewswire\/ — Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced a poster presentation at the virtual 62nd<\/sup> American Society of Hematology (ASH) Annual Meeting for the ongoing Phase 1 dose-escalation clinical trial for its CD74-targeted antibody drug conjugate (ADC) STRO<\/span>-001 for patients with late-line Non-Hodgkin Lymphoma (NHL). Additionally, data were presented from preclinical studies conducted in collaboration with researchers from the Fred Hutchinson Cancer Research Center.<\/p>\n

“With three product candidates in the pipeline actively enrolling patients\u2014STRO-001, STRO-002, our folate receptor alpha- (FolR\u03b1) targeting ADC, and CC-99712 in partnership with Bristol Myers Squibb, a BCMA-targeting ADC\u2014Sutro is working on addressing unmet needs via targeted therapies that can tackle cancer evolution,” said Bill Newell<\/span>, Sutro’s Chief Executive Officer. “The encouraging safety and preliminary efficacy clinical data presented at ASH on STRO-001 for the treatment of late-line NHL further validates our platform and unique approach to ADC design, creating potential first-in-class and\/or best-in-class therapeutic candidates.”<\/p>\n

\n STRO-001 Phase 1 Dose Escalation Interim Data
<\/b>STRO-001-BCM1 is an ongoing first-in-human, phase 1 dose-escalation study evaluating the safety, tolerability, and preliminary antitumor activity of STRO-001 in adults with B-cell malignancies. The study is ongoing, and data presented at ASH included results from the NHL cohort. There were 21 NHL patients treated and 18 evaluable patients for response. Patients had a median of 5 prior therapies. 6\/21 patients (29%) had previous stem cell transplant or CAR-T therapy. Data as of October 30, 2020<\/span> are as follows:<\/p>\n